The Vitals | Pioneering Ketamine Treatment for Depression

Why It Matters

Ketamine’s rapid, robust effects provide a lifeline for treatment‑resistant patients, potentially reducing suicide risk and expanding therapeutic options for depression and PTSD.

Key Takeaways

• Ketamine works within hours, unlike weeks for traditional antidepressants.
• Early Yale and NIMH studies proved rapid efficacy in treatment‑resistant depression.
• Mount Sinai introduced active‑placebo controls and repeated‑dose protocols.
• Ketamine shows promising rapid relief for PTSD symptoms, especially nightmares.
• FDA‑approved Spravato commercializes ketamine, expanding global clinical use.

Summary

The Vitals episode brings together Mount Sinai psychiatrists to discuss ketamine’s emergence as a fast‑acting antidepressant and its expanding role in treating depression and PTSD.

Dr. Dennis Charney recounts the mid‑1990s Yale experiments that showed a single sub‑anesthetic ketamine infusion lifted mood within hours, a finding later replicated at NIMH and validated by larger, multi‑site trials that used midazolam as an active placebo. These studies demonstrated efficacy in patients who had failed conventional monoamine‑based drugs, leading to FDA approval of the intranasal formulation Spravato.

Clinicians share vivid patient anecdotes—a 50‑year‑old woman who felt “a weight lifted” after one infusion and a 9/11 responder whose trauma‑triggered anxiety subsided after repeated doses—illustrating ketamine’s rapid impact on both depressive and PTSD symptoms, including nightmares and intrusive memories.

The data reshapes psychiatric practice by offering an alternative to weeks‑long antidepressant regimens and electroconvulsive therapy, prompting ongoing research into optimal dosing schedules and broader indications, while raising questions about long‑term safety and accessibility.

Original Description

How did ketamine evolve from an anesthetic to one of the most important mental health treatment breakthroughs in decades?

In this episode of The Vitals, guest host Dennis Charney, MD sits down with specialists, James Murrough , MD, PhD, and Adriana Feder, MD, to explore the science behind ketamine treatment for depression and PTSD—and why it may offer hope for patients who have not responded to traditional therapies.

The conversation traces the origins of ketamine research to the pioneering clinical work conducted at Mount Sinai. The doctors explain how ketamine differs from standard antidepressants, why it can work within hours instead of weeks, and how it is helping patients with treatment-resistant depression and suicidal thinking.

The panel also discusses:

How ketamine became the FDA-approved treatment Spravato

Why researchers believe ketamine increases neuroplasticity in the brain

The growing evidence for ketamine in treating PTSD

How psychotherapy may enhance ketamine’s long-term effects

Why patients should not lose hope, even after years of severe symptoms

To learn more about Mount Sinai’s Depression and Anxiety Center or to book an appointment with a Mount Sinai expert, visit the Mount Sinai Health System’s website: https://icahn.mssm.edu/research/depression-anxiety-center

Instagram: https://www.instagram.com/mountsinaidepression/

Subscribe to The Vitals and the Mount Sinai Health System’s other podcasts on YouTube, Apple Podcasts, Spotify, or wherever you get your podcasts.

00:00 – Introduction: The Promise of Ketamine Treatment

01:35 – How Ketamine Was First Discovered as an Antidepressant

05:35 – Early Skepticism and the First Mount Sinai Studies

09:35 – Patients Experiencing Rapid Relief from Depression

11:45 – Could Ketamine Help PTSD Patients Too?

15:00 – The First Ketamine Studies for PTSD

17:05 – Real Patient Stories: Fear, Trauma, and Recovery

19:20 – Why Psychotherapy May Enhance Ketamine Treatment

22:20 – Ketamine-Assisted Psychotherapy Explained

27:10 – Exposure Therapy, Fear Extinction, and PTSD Recovery

32:20 – Ketamine and Suicidal Thinking

37:15 – What Brain Imaging Reveals About Depression and PTSD

42:00 – Final Message: There Is Hope